New combo therapy aims to tackle colorectal cancer liver spread
NCT ID NCT06848465
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial is testing whether adding low-dose radiation to standard immunotherapy and chemotherapy is safe for people with colorectal cancer that has spread only to the liver. About 9 to 18 participants will receive the combination treatment. The main goal is to check for side effects and see if the approach is feasible.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Low-dose radiotherapy, tislelizumab (immunotherapy), oxaliplatin and capecitabine (chemotherapy)
What this could lead to
If this combination proves safe and feasible, it could point toward a new treatment option for colorectal cancer that has spread only to the liver.
What could go wrong
This is a very early phase 1 trial with only 9-18 participants, so the main goal is safety, not effectiveness. The combination may cause significant side effects and might not shrink tumors.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Army Medical Center
RECRUITINGChongqing, Chongqing Municipality, 400042, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Daping Hospital, Army Medical University
ACTIVE_NOT_RECRUITINGChongqing, Chongqing Municipality, 400042, China